NASDAQ: KYNBKyntra Bio Inc Stock
$9.22-0.28 (-2.95%)
Updated Jan 9, 2026
KYNB Price
$9.22
Fair Value Price
-$1.28
Market Cap
$37.30M
52 Week Low
$4.85
52 Week High
$21.94
P/E
0.17x
P/B
-2.19x
P/S
-0.42x
PEG
N/A
Dividend Yield
N/A
Revenue
-$118.09M
Earnings
$215.65M
Gross Margin
82.7%
Operating Margin
-182.34%
Profit Margin
-182.6%
Debt to Equity
-7.02
Operating Cash Flow
-$17M
Beta
1.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KYNB Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KYNB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KYNB
Ranked#158 of 490
Ranked#158 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.71 | A | |
| $161.13 | A | |
| $6.10 | A |
Be the first to know about important KYNB news, forecast changes, insider trades & much more!
KYNB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KYNB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KYNB ($9.22) is overvalued by 819.46% relative to our estimate of its Fair Value price of -$1.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KYNB ($9.22) is not significantly undervalued (819.46%) relative to our estimate of its Fair Value price of -$1.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KYNB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more KYNB due diligence checks available for Premium users.
Valuation
KYNB fair value
Fair Value of KYNB stock based on Discounted Cash Flow (DCF)
Price
$9.22
Fair Value
-$1.28
Undervalued by
819.46%
KYNB ($9.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KYNB ($9.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KYNB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.17x
Industry
176.2x
Market
45.1x
KYNB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KYNB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
KYNB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.19x
Industry
5.49x
KYNB's financial health
Profit margin
Revenue
$1.1M
Net Income
$200.6M
Profit Margin
18,646.5%
KYNB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KYNB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$137.0M
Liabilities
$119.5M
Debt to equity
-7.02
KYNB's short-term assets ($133.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KYNB's short-term assets ($133.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KYNB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KYNB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$87.2M
Financing
-$85.9M
KYNB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KYNB vs Biotech Stocks
Kyntra Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.